The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply reports and data to the agency during the approved clinical trials rather than at completion. The agency said it had already completed two proof-of-concept trials using RTCT reporting. As part of the announcement, the FDA issued a request for information on a proposed pilot program to assess AI’s impact on efficiency, speed and quality of decision-making in early phase clinical trials. The agency will accept comments, submitted through regulations.gov, for 30 days following publication in the Federal Register.

Headline
The AHA will host a webinar Dec. 1 at 1 p.m. ET on how to create and build an effective artificial intelligence training program. Attendees will learn how to…
Headline
A Gallup survey published Nov. 9 on patient comfort with artificial intelligence in care found that 56% of U.S. adults who visited a primary care provider in…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…
Headline
The AHA Nov. 3 launched a new webpage, Artificial Intelligence Policy and Advocacy, featuring AHA policy letters, statements, fact sheets, news and other…
Chairperson's File
Public
Leadership matters, especially during times of change and transformation in healthcare. That’s why I was pleased to sit down with Steve Walsh, who joined the…